EMIT-d.a.u. monoclonal amphetamine/methamphetamine assay. II. Detection of methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA).
The cross-reactivity, stereoselectivity and clinical performance of the EMIT-d.a.u. monoclonal amphetamine/methamphetamine immunoassay (EM) for the detection of methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) in urine was evaluated. The cut-off concentrations of racemic MDA and MDMA were found to be approximately 800 ng/ml and 3000 ng/ml, respectively. The EM assay demonstrated a high selectivity for the S(+) isomer of both MDA and MDMA. Urines collected over a 24-h period from rats administered 20 mg i.v. racemic MDMA were all positive when analyzed by the EM assay. The EM was found vastly superior to the EMIT d.a.u. polyclonal amphetamine/methamphetamine assay for the detection of MDA and MDMA. The EM assay displayed sufficient sensitivity for detection of these drugs following clinical intoxication.
Poklis
A
A
Department of Pathology, Medical College of Virginia Hospitals, Virginia Commonwealth University, Richmond 23298-0597.
Fitzgerald
R L
RL
Hall
K V
KV
Saady
J J
JJ
D015104:3,4-Methylenedioxyamphetamine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000737:chemistry / Q000652:urine*; D000661:Amphetamine / Q000737:chemistry / Q000652:urine*; D000818:Animals; D003429:Cross Reactions; D015198:Designer Drugs / Q000008:administration & dosage; D008401:Gas Chromatography-Mass Spectrometry; D007118:Immunoassay; D007275:Injections, Intravenous; D008297:Male; D018817:N-Methyl-3,4-methylenedioxyamphetamine; D051381:Rats; D012680:Sensitivity and Specificity; D013237:Stereoisomerism
D015198:Designer Drugs; D015104:3,4-Methylenedioxyamphetamine; D000661:Amphetamine; D018817:N-Methyl-3,4-methylenedioxyamphetamine